Please contact Dr Tim Witney ([email protected]) prior to application to discuss your suitability for the project.
Applications are made via the King’s admissions portal. Student applications will be shortlisted based on their suitability to the programme and their track record of research experience at BSc and post-graduate level.
For key dates and for further information please see: View Website
1 McCormick, PN, et al. (2019). Assessment of tumor redox status through (S)-4-(3-[18F]fluoropropyl)-L-glutamic acid positron emission tomography imaging of system xc- activity. Cancer Res. 79, pp.853-863.
2 Greenwood, HE et al., (2019). Measurement of tumor antioxidant capacity and prediction of chemotherapy resistance in preclinical models of ovarian cancer by positron emission tomography. Clin Cancer Res 25, pp.2471-2482.
3 Moore, K et al. 2018). Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med; 379:2495-2505
4 O'Carrigan B, et al. (2016). Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with Carboplatin (CP) incorporating pharmacodynamics (PD) studies. J Clin Oncol. 34 (Suppl 2504).
5 Ng T, et al. (2018). The use of exosome and immune profiling to analyze a Phase 2 study on the addition of patritumab or placebo to cetuximab and a platinum agent for recurrent / metastatic head and neck cancer (R/M HNSCC) patients. J Clin Oncol. 3 6(Suppl 6043).